• Fractyl Health swung to net income of $9.22 million, helped by other income of $30.04 million.
• Operating loss narrowed 15.9% to $20.82 million as total operating expenses fell 15.9% to $20.82 million.
• Research and development expense dropped 19.7% to $15.6 million, while selling, general and administrative costs edged down 1.9% to $5.22 million.
• Cash and cash equivalents totaled $63.2 million, with management expecting it to fund operating needs into early 2027 while flagging substantial doubt about the ability to continue as a going concern for at least one year.
• Revita REMAIN-1 midpoint cohort data showed 4.5% weight regain at six months versus 7.5% for sham (p=0.07, one-sided), while FDA pre-submission feedback acknowledged Revita DMR System safety profile as consistent with a Class II device classification.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fractyl Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-219373), on May 12, 2026, and is solely responsible for the information contained therein.